KOL Views Results: Leading cardiologist says REDUCE-IT trial will be a big boost to Vascepa and Vascepa alone
FirstWord hosted an expert call this week with Michael Davidson – professor and director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine – to discuss top-line results from the Phase III REDUCE-IT trial in which Amarin’s Vascepa (icosapent ethyl) cut the risk of cardiovascular events by 25 percent versus placebo, and the potential impact on prescribing patterns.